Teaching Old Drugs New Tricks May 15, 2008
Compounds like Eli Lilly's (NYSE: LLY) Cymbalta or Cephalon's (Nasdaq: CEPH) Provigil have found on- and off-label uses to treat multiple seemingly unrelated conditions ... Cephalon's Long Shot Falls Short. (MSNBC -- Business)
Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA May 7, 2008
Cephalon to Hold Conference Call with Investors Today at 5:30 p.m. EDT FRAZER, Pa. May 6 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that a Joint Advisory Committee to the U.S. Food and Drug Administration (FDA) voted not to recommend approval of an expanded label for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain conditions ... "We are disappointed with the recommendation of the... (PR Newswire)
2nd UPDATE: FDA Panel Doesn't Back Expanded Use Of Fentora May 7, 2008
did not recommend approval for expanding the use of Cephalon Inc.'s (CEPH) Fentora, a powerful pain reliever, to non-cancer patients ... The panel said it wants Cephalon to compare Fentora with similar pain killers ... "Although we are disappointed, we are not surprised with the results [of the vote]," said Frank Baldino, Cephalon chairman and chief executive in a conference call Tuesday. (CNNMoney.com)
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Jan 1, 2008
Dec. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of TREANDA(R) (bendamustine HCl) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) who have progressed during or following treatment with rituximab or a rituximab-containing regimen ... In September 2007, Cephalon submitted an NDA requesting approval of... (PR Newswire)
FDA Warns on Cephalon's Provigil Oct 25, 2007
FDA Warns on Cephalon's Provigil - News sis - Winners s - CEPH - CEPH ... FDA Warns on Cephalon's Provigil ... The Food and Drug Administration posted a safety alert Wednesday on Cephalon's ( - - ) sleep drug Provigil. (TheStreet.com)
HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes Sep 18, 2007
6 Sangamo BioSciences Inc SGMO 1850518888 Cepheid Inc CPHD 684562667 ... 25 Cephalon Inc CEPH 80128698 ... 3 Cephalon Inc CEPH 79747779. (PR Newswire)
Cephalon Provides Update Related to NUVIGIL(TM) New Drug Application Mar 31, 2007
March 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has received an approvable letter, together with draft labeling, from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for NUVIGIL(TM) (armodafinil) Tablets [C-IV] for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) and shift work sleep disorder (SWSD) ... D., Chairman and CEO of Cephalon ... Cephalon also plans... (PR Newswire)
EARLY TREATMENT MAY PREVENT SEVERE NPH SYMPTOMS Dec 28, 2006
STAFF 12/27/2006 Normal pressure hydrocephalus (hy dro CEPH a lus) is a brain disorder that occurs when the flow of cerebrospinal fluid is blocked ... Normal pressure hydrocephalus (NPH) can occur in people of any age, but it is most common in the elderly population ... Normal pressure hydrocephalus is often a reversible or treatable disorder. (Tyler Morning Telegraph, TX)
Cephalon shares up on FDA notice Jul 1, 2006
Fentora is a sugar-free tablet that contains fentanyl, the same active ingredient found in Actiq, Cephalon's cancer pain medicine made as a lozenge attached to a stick that resembles a lollipop ... Cephalon (NASDAQ: CEPH) of Frazer, Pa. (Philadelphia Business Journal, PA)
Cephalon Receives Approvable Letter for FENTORA(TM) (fentanyl buccal tablet) for Management of Breakthrough Pain in Patients with Cancer Jun 30, 2006
June 29 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for FENTORA(TM) (fentanyl buccal tablet) [C-II ... "We believe FENTORA will extend the leadership position of Cephalon in the development of innovative medications for the management of breakthrough pain in patients with cancer." Cephalon intends to submit a response to the FDA by the end of July ... On a separate matter, Barr... (PR Newswire)
Coram, Inc. Named Distributor of Vivitrol Jun 2, 2006
DENVER, June 1, 2006 (PRIMEZONE) -- Coram, Inc., a leading national provider of specialized home infusion and specialty pharmaceutical distribution services, announced today that it has been selected by Alkermes, Inc. (NasdaqNM: - ), and Cephalon, Inc. (NasdaqNM: - ) to be a national provider of Vivitrol(tm), the first once-monthly injectable medication for the treatment of alcohol dependence ... We are pleased to confirm that Coram was selected to be in our network of specialty pharmacy... (Primezone Releases)
Stocks to watch Feb 15, 2006
Cephalon Inc. ( : CEPH, , , Last. Sponsored by. (CBS MarketWatch - Front Page)
Movers & Shakers Jan 27, 2006
Cephalon Inc. (: CEPH , , , Last ... -based Cephalon now expects to launch Sparlon during the second quarter. (CBS MarketWatch - Front Page)
